ADAR1i-124 |
Catalog No.GC79067
One-Click Copy Product Info
|
ADAR1i-124 is an A-to-I RNA editing inhibitor by inhibiting the catalytic activities of both ADAR1p150 and ADAR1p110.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vitro, ADAR1i-124 (0-200 μM; 2 h) potently inhibits ADAR1p150-mediated A-to-I RNA editing in vitro with IC50 values of 8.8 μM (position 2) and 6.5 μM (position 5)[1]. ADAR1i-124 (300 μM; 2 h) does not inhibit ADAR2-mediated A-to-I RNA editing in vitro[1]. ADAR1i-124 binds selectively to ADAR1p110 with higher affinity than ADAR2 and does not bind to GAPDH[1]. ADAR1i-124 (10 μM; 12 h) induces unedited dsRNA located with MDA5 within the filament structures in mouse Yumm1.7 cutaneous melanoma cells[1]. ADAR1i-124 (10 μM; 12 h) decreases A-to-I editing and prompts the transition of certain dsRNAs from A-form to Z-form in Yumm1.7 cells[1]. ADAR1i-124 (48 h) induces dose-dependent cytotoxicity against mouse (Yumm1.7 CM, HSG2 OC) and human (WM4223 AM, WM3000 CM) cancer cells with IC50 values of 2.3, 1.2, 1.1 and 6.6 μM[1]. ADAR1i-124 (10 μM; 24 h) activates IFN signaling in Yumm1.7 melanoma and HGS2 OC cells[1]. ADAR1i-124 (10 μM; 24 h) induces apoptosis in HeLa and Yumm1.7 cells and also induces necroptosis activated by the ZBP1 pathway in Yumm1.7 cells[1].
References:
[1]. Minakuchi M, et al. Identification of ADAR1i-124: The first effective A-to-I RNA editing inhibitor with promising cancer therapeutic potential. iScience. 2026;29(2):114615. Published 2026 Jan 2.
| Cas No. | SDF | ||
| Formula | C17H12ClN3O2 | M.Wt | 325.75 |
| Solubility | DMSO: 100 mg/mL (306.98 mM; Need ultrasonic) | Storage | Store at -20°C, protect from light |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0698 mL | 15.3492 mL | 30.6984 mL |
| 5 mM | 614 μL | 3.0698 mL | 6.1397 mL |
| 10 mM | 307 μL | 1.5349 mL | 3.0698 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)